ClinicalTrials.gg

TargetBeta

TMPRSS6

transmembrane serine protease 6 · also FLJ30744, MT2 · Type II transmembrane serine proteases

3 programs in company-led studies act on TMPRSS6, from 3 companies: 2 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
AG-236ruleAgios Pharmaceuticalsphase 322 running–the studies' text
sapablursenruleIonis Pharmaceuticalsphase 341 running–NCIt
Anti-TMPRSS6 Monoclonal Antibody DISC-3405ruleDisc Medicinephase 264 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.